Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model

Metabolism: Clinical and Experimental
Toshiyuki FunatsuKeiji Miyata

Abstract

Although postprandial hypertriglyceridemia has drawn attention as an independent risk factor of cardiovascular disease, there is no established animal model that shows a physiological transitory change in lipoprotein metabolism after ingestion of a fatty meal. We developed an animal model of postprandial hypertriglyceridemia using sucrose-fed rats, and used this model to evaluate the effect of atorvastatin on this condition. Compared with normal rats, sucrose-fed rats orally loaded with olive oil showed a high and prolonged increase in plasma triglyceride (TG) concentration accompanied by both an increase in TG secretion and decrease in TG clearance. Atorvastatin (30 mg/kg orally) for 2 weeks reduced not only fasting plasma TG concentration, but also the postprandial TG concentration. Atorvastatin also suppressed rates of TG secretion in both chylomicron (CM)-rich (d < 0.96 g/mL) and very-low-density lipoprotein (VLDL) (d = 0.96 to 1.006 g/mL) fractions after oral fat loading. Further, atorvastatin improved the elimination time of exogenous TG emulsion only in the nonfasted, namely, high plasma TG condition. These results indicate that this animal model satisfactorily replicates the postprandial hypertriglyceridemia observed in...Continue Reading

References

Jan 1, 1990·Drug Metabolism Reviews·D E Duggan, S Vickers
Apr 1, 1987·Diabetes/metabolism Reviews·K PyöräläM Uusitupa
Apr 1, 1987·Diabetes/metabolism Reviews·H N Ginsberg
Nov 1, 1987·Metabolism: Clinical and Experimental·R A GutmanY B Lombardo
Sep 1, 1983·The Journal of Clinical Endocrinology and Metabolism·M R TaskinenT Sane
Sep 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·T KitaJ L Goldstein
Mar 1, 1994·Atherosclerosis·F KarpeA Hamsten
Feb 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M SyvänneM R Taskinen
Jun 22, 1999·Clinical Cardiology·S H Gianturco, W A Bradley
Nov 30, 2000·The Journal of Clinical Endocrinology and Metabolism·K G ParhoferP Schwandt
Jun 20, 2001·Diabetes, Obesity & Metabolism·J R Burnett, G F Watts
Mar 8, 2002·Atherosclerosis·Sebely PalJohn C L Mamo
Oct 16, 2008·Journal of Lipid Research·Anne P BeigneuxStephen G Young

❮ Previous
Next ❯

Citations

Jan 1, 2009·Expert Opinion on Drug Discovery·Andrea Cignarella
Jul 13, 2016·Expert Opinion on Drug Metabolism & Toxicology·Jonathan G Stine, Patrick G Northup
Mar 28, 2012·Phytotherapy Research : PTR·Jamile M FerreiraMaria Goretti R deQueiroz
Sep 9, 2015·Liver International : Official Journal of the International Association for the Study of the Liver·Jonathan G Stine, Naga Chalasani

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.